Teleflex Incorporated (NYSE:TFX) announced a quarterly dividend on Thursday, July 30th, Zacks reports. Shareholders of record on Friday, August 14th will be given a dividend of 0.34 per share by the medical technology company on Tuesday, September 15th. This represents a $1.36 annualized dividend and a yield of 0.36%. The ex-dividend date of this dividend is Thursday, August 13th.
Teleflex has a payout ratio of 13.6% meaning its dividend is sufficiently covered by earnings. Equities analysts expect Teleflex to earn $13.38 per share next year, which means the company should continue to be able to cover its $1.36 annual dividend with an expected future payout ratio of 10.2%.
TFX opened at $373.10 on Friday. The company has a current ratio of 3.38, a quick ratio of 2.38 and a debt-to-equity ratio of 0.78. The stock has a market capitalization of $17.88 billion, a PE ratio of 35.34, a PEG ratio of 2.92 and a beta of 1.01. Teleflex has a 1-year low of $221.27 and a 1-year high of $405.07. The firm has a 50-day moving average price of $368.12 and a two-hundred day moving average price of $350.56.
Teleflex (NYSE:TFX) last posted its quarterly earnings data on Thursday, July 30th. The medical technology company reported $1.93 earnings per share for the quarter, beating the consensus estimate of $1.25 by $0.68. The firm had revenue of $567.00 million during the quarter, compared to analysts’ expectations of $537.85 million. Teleflex had a net margin of 18.99% and a return on equity of 17.15%. The company’s quarterly revenue was down 13.1% compared to the same quarter last year. During the same quarter last year, the company posted $2.66 EPS. On average, research analysts predict that Teleflex will post 10.14 EPS for the current year.
In other Teleflex news, Director Stephen K. M.D. Klasko sold 200 shares of the firm’s stock in a transaction that occurred on Monday, July 27th. The shares were sold at an average price of $386.35, for a total transaction of $77,270.00. Following the sale, the director now directly owns 1,321 shares in the company, valued at approximately $510,368.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CAO John Deren sold 1,093 shares of the firm’s stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $330.10, for a total transaction of $360,799.30. Following the sale, the chief accounting officer now owns 1,253 shares in the company, valued at $413,615.30. The disclosure for this sale can be found here. 2.21% of the stock is owned by company insiders.
TFX has been the topic of several recent research reports. JMP Securities reduced their target price on shares of Teleflex from $395.00 to $385.00 and set a “market outperform” rating on the stock in a research note on Friday, May 1st. Needham & Company LLC reaffirmed a “buy” rating and issued a $431.00 target price on shares of Teleflex in a research note on Thursday, April 30th. SVB Leerink raised their target price on shares of Teleflex from $400.00 to $425.00 and gave the company an “outperform” rating in a research note on Thursday, June 4th. UBS Group reduced their target price on shares of Teleflex from $440.00 to $410.00 and set a “buy” rating on the stock in a research note on Friday, May 1st. Finally, Piper Sandler reduced their price objective on shares of Teleflex from $425.00 to $375.00 and set an “overweight” rating on the stock in a research note on Friday, May 1st. Two analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $389.40.
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease.
Further Reading: How can you know how many shares are floating?
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.